Mouse Anti-FRMD5 Recombinant Antibody (CBXF-1798) (V2LY-1225-LY101)

Lu, S., Ma, M., Mao, X., Bacino, C. A., Jankovic, J., Sutton, V. R., ... & Bellen, H. J. (2022). De novo variants in FRMD5 are associated with developmental delay, intellectual disability, ataxia, and abnormalities of eye movement. The American Journal of Human Genetics, 109(10), 1932-1943.

Gaweł, A. M., Ratajczak, M., Gajda, E., Grzanka, M., Paziewska, A., Cieślicka, M., ... & Godlewska, M. (2021). Analysis of the Role of FRMD5 in the Biology of Papillary Thyroid Carcinoma. International Journal of Molecular Sciences, 22(13), 6726.

Mao, X., Tey, S. K., Ko, F. C. F., Kwong, E. M. L., Gao, Y., Ng, I. O. L., ... & Yam, J. W. P. (2019). C-terminal truncated HBx protein activates caveolin-1/LRP6/β-catenin/FRMD5 axis in promoting hepatocarcinogenesis. Cancer letters, 444, 60-69.

Gao, H., Yin, R. X., Zhang, Q. H., Qiu, L., Khounphinith, E., Wang, D. S., & Li, K. G. (2018). Association of the FRMD5 rs2929282 polymorphism and serum lipid profiles in two Chinese ethnic groups. International Journal of Clinical and Experimental Pathology, 11(7), 3494.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols